Biotech Showcase 2019 Investment Trends Survey
|
|
- Anthony Griffin
- 5 years ago
- Views:
Transcription
1 Demy-Colton and EBD Group Biotech Showcase 2019 Investment Trends Survey December 7, 2018
2 Survey Overview Survey included 10 questions on biotech industry investment trends for 2019 Survey was sent to the 2018 list of registered Biotech Showcase attendees 80 people provided responses
3 QuesBon 1: Which of the following best describes your professional role? Venture capitalist Corporate investor Investment banker/banker Private investor Buy side/sell side research analyst Executive or upper management of biotech or pharma company Research and development executive Government official Professional service provider Press and media
4 Survey Responder Demographics - Chart Professional Press and media, 3.75% service provider, 1 Buy side/sell side research analyst Corporate Investor Government official, Investors, 33.75% 5.00% 7.50% 16.25% Investment Banker Private Investor Venture Capitalist Executives and Upper Management, 48.75% Based on 80 responses to survey
5 Survey Responder Demographics - Table RESPONDER OCCUPATION # OF RESPONDERS PERCENT OF TOTAL INVESTOR (Total of subcategories below) % Venture capitalist % Corporate investor 2 Investment banker/banker % Private investor % Buy side/sell side research analyst 2 EXECUTIVE/UPPER MANAGEMENT (Total of subcategories below) % Executive or upper management of biotech or pharma company % Research and development executive % Government official 2 Professional service provider 9 1 Press and media % Total Responders 80
6 Question 2: Overall, you expect to see in life science investments in 2019 compared to Increase Decrease No change
7 The majority of life science investors and executives expect to see an increase in investment during % 60% 50% 7.50% Investors Executives Media, Services, Gov 40% 37.50% 30% 20% 6.25% 10% 0% 20.00% 3.75% 8.75% 6.25% 7.50% Increase Decrease No Change
8 Sixty percent of life science investors expect to see an increase in investment in % 60% 50% 40% 30% 20% 10% 0% Increase Decrease No Change
9 Question 3: Of the following areas, which do you think is poised to have the biggest nearterm breakthrough? Alzheimer s and CNS diseases Cell and gene therapy Immuno-oncology NASH RNA therapeutics Rare and orphan disease Digital medicine Other (please specify)
10 Of the major therapeutic areas, biotech leaders think cell and gene therapy is poised to have biggest breakthrough in % 30% 3.75% 25% 20% % 15% 10% 5% 0% Cell and gene therapy % 7.50% 5.00% 6.25% 3.75% Immuno-oncology Rare and orphan disease Digital medicine Alzheimer s and CNS 5.00% NASH RNA therapeutics 3.75% Other
11 Question 4: Of the factors listed below, what is the biggest challenge biotech companies face in securing funds in the coming year? Crowded market or sector Economic volatility Inexperienced management team Lack of achieved milestones Inability to manage pipeline progression or clinical trials Other (please specify)
12 Biggest challenges for securing funds in the coming year are crowded markets, economic volatility, and inexperienced management 25% 20% 15% 10% 5% 0% Crowded market or sector Economic volatility Inexperienced management team Lack of achieved milestones Inability to manage pipeline progression or clinical trials Other
13 US Outlook
14 Question 5: Do you expect the recent stock market volatility to affect overall biotech investment in 2019? Yes No Unsure
15 Most biotech leaders expect the stock market volatility to have an overall effect on 2019 investments 70% 60% 50% 1 40% 27.50% 30% 20% 3.75% 10% 20.00% % 0% 7.50% 6.25% Yes No Unsure
16 Question 6: What US city/region will see the biggest percent increase in investment dollars in the biotechnology industry in 2019? Boston Los Angeles New York Philadelphia Raleigh-Durham San Diego San Francisco Seattle Other (please specify)
17 Boston holds #1 seat for predicted influx of investment dollars among the major U.S. cities 35% 30% 25% 10.00% 20% 15% 1 10% 5% 0% 8.75% 3.75% % 5.00% 8.75% 7.50% 5.00% 3.75% 3.75% 3.75% Boston San Diego San Francisco New York Other* Los Angeles Philadelphia Raleigh-Durham Seattle *Texas (3), New Jersey, Maryland
18 Investors think New York is the next city, after Boston and San Francisco, to see an influx of investment dollars in % 9% 8% 7% 6% 5% 4% 8.75% 7.50% 3% 2% 1% 0% Boston San Francisco 5.00% New York 3.75% 3.75% Other* Philadelphia San Diego Los Angeles Raleigh-Durham Seattle *Texas (3), New Jersey, Maryland
19 Global Outlook
20 Ques%on 7: Which region outside the United States will see the biggest percent increase in investment dollars in the biotechnology industry in 2019? China UK Germany Benelux Japan France Spain Scandinavia South Korea Other*
21 China predicted to see the biggest percent increase in 2019 biotech investment dollars when compared to other global biotech hot spots 50% 45% 40% 7.50% 35% 30% 25% 25.00% 20% 15% 10% 5% 0% 5.00% % 5.00% 5.00% 6.25% 3.75% China UK Germany Benelux Japan France Spain Scandinavia S. Korea Other* *Israel (3), Singapore, Unspecified
22 Question 8 & 9: What impact will US/China trade war have on strategy for investment, partnerships, or expansion in China? Negative Impact No Impact Will this trade war have a long-term impact on biotech investments originating from China? Yes No Unsure
23 While life science leaders do not expect the U.S./China trade war to have an impact on their regional strategies, they do expect it will have long-term impact on investments coming from that region Investor and Executive Responses 60% 50% 40% % 20% 33.33% 7.58% 18.18% Negative Impact No Impact More than half of biotech leaders think the trade war with China will have no impact on their strategy for partnerships, investments, or expansion in this region 10% 0% 15.15% 13.64% 12.12% Yes No Unsure Investors Executives One third of biotech execuaves think the trade war will have a long term impact on investments originaang from China
24 Question 10: What impact will the UK exit from the EU in March 2019 have on investment in the regions below? United Kingdom, North America, European Union, Other Global Markets Increase Decrease No change
25 When the UK exits from the EU in March, investors expect to see a decrease in investments in the UK while other markets will see an increase or remain unchanged United Kingdom North America European Union Other Global Markets 10% 15% 76% 61% 34% 5% 30% 30% 41% 75% 19% 6% Increase Decrease No Change
Employment Trends & Salary Survey
Employment Trends & Salary Survey 2017-18 in partnership with www.sciproglobal.com Contents Introduction to SciPro...3 Executive Summary...4 Section 1 Demographics...5-10 Section 2 Hiring Trends...11-18
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationAdAlta Limited (ASX:1AD) Quarterly Cash Flow Statement
31 January 2017 Company Announcements/Australian Securities Exchange AdAlta Limited (ASX:1AD) Quarterly Cash Flow Statement Highlights Received FDA Orphan Drug Designation for AD-114 in IPF Positive Pre-clinical
More informationAddressing access to healthcare
Addressing access to healthcare Karl Mahler Head Investor Relations René Imhof Head Operational Pricing Swiss Sustainability Leaders SRI Conference Buonas, 17 November 2014 This presentation contains certain
More informationThe Funding Landscape for Small Biopharma Ventures,
HEALTHCARE The Funding Landscape for Small Biopharma Ventures, 2010-2015 Trends, strategies and priorities By Gaurav Misra Gaurav Misra Gaurav Misra specializes in pharmaceutical licensing, valuations
More informationSunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights. VALOR Trial Reaches Prespecified Events for Unblinding
Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights August 5, 2014 7:00 AM ET VALOR Trial Reaches Prespecified Events for Unblinding Sunesis to Host Conference Call
More informationGenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris
Press Release GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris Capital increase of approximately 40 million, which may be increased to a maximum of approximately
More informationUNC KENAN-FLAGLER: DISCUSSION MATERIALS MARCH 2014
UNC KENAN-FLAGLER: DISCUSSION MATERIALS MARCH 2014 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,125,578,204.37 Fund Inception Date 03/04/2000 Number of Issuers 93 Bloomberg
More informationCytori Reports First Quarter 2014 Business and Financial Results
CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Reports First Quarter 2014 Business and Financial Results San Diego, CA, May 12, 2014 Cytori Therapeutics (NASDAQ:
More informationIpsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates
PRESS RELEASE Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates Paris (France), 26 April 2018 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical
More informationICON plc and subsidiaries
ICON plc and subsidiaries Interim financial statements Six months ended 30 June 2012 Registered number 145835 ICON plc and subsidiaries Interim Management Report and Condensed Consolidated Financial Statements
More information0 Preliminary Results December Preliminary Results December March 2011
0 Preliminary Results December 2010 Preliminary Results December 2010 23 March 2011 Agenda Introduction 2010 Results International business Acquisition of Atomic PR Citigate Grayling Red Huntsworth Health
More informationHEARING STATEMENT. United States Senate Committee on Banking, Housing, and Urban Affairs
HEARING STATEMENT United States Senate Committee on Banking, Housing, and Urban Affairs Spurring Job Growth Through Capital Formation While Protecting Investors December 1, 2011 Executive Summary The Biotechnology
More informationHow to value your start-up Dr. Patrik Frei January 2016 San Francisco
How to value your start-up Dr. Patrik Frei January 2016 San Francisco Overview Introduction to Valuation Valuation of start-up companies Valuation of a therapeutic Product Q & A 2 Venture Valuation Mission
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month
More informationNews Release. Transaction Highlights
News Release Proposed Acquisition of Shire plc by Takeda Creates a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan Better positions Takeda to deliver highly-innovative
More informationHeidelberg Pharma announces financial figures for fiscal year 2017 and provides business update
PRESS RELEASE Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update Financials in line with guidance on the back of positive revenue performance Corporate actions
More informationGLOBAL BREXIT BAROMETER 2018
GLOBAL BREXIT BAROMETER 2018 Tuesday 20 March 2018 Gary Baker, CFA, Managing Director EMEA and Industry and Policy Research, CFA Institute Rhodri Preece, CFA, Head of Industry Research, CFA Institute Will
More informationehealth Inventory Report of Major Medical Health Plans Available Off of Government Exchanges
ehealth Inventory Report of Major Medical Health Available Off of Government Exchanges February 2014 Introduction Beginning January 1, 2014, all new major medical health insurance plans were required to
More informationBiotech Financing Update. Dec 2017-Feb 2018
Biotech Financing Update Dec 2017-Feb 2018 Biotech Financing Update Overall figures These figures capture biotech financing data from December 2017 and take a first look at how the sector is doing in 2018
More informationJefferies Global Healthcare Conference
Jefferies Global Healthcare Conference June 7, 2012 2012 PAREXEL International Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationVenture Capital and Company Valuations in Biotech
Venture Capital and Company Valuations in Biotech Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Swiss
More informationSmall-Cap Research. Oncolytics Biotech Inc. November 28, 2017 John D. Vandermosten, CFA (ONCYF - OTCQX) Cash & Validation: REOLYSIN is Going to Asia
Small-Cap Research November 28, 2017 John D. Vandermosten, CFA 312-265-9588 / jvandermosten@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Oncolytics Biotech Inc. Cash & Validation:
More informationFinancing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.
Financing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.0, Prague Venture Valuation Mission Independent assessment and valuation of
More informationMarket Allocation Platform Guiding investment decisions to maximize ROI. Tourism Economics
Market Allocation Platform Guiding investment decisions to maximize ROI Tourism Economics core services Travel data and forecasts for 190 countries, 50 states, and 300 cities Policy analysis and recommendations
More informationWhat you need to know to succeed in doing deals and fundraising Dr. Patrik Frei May 2014 Seoul BioKorea
What you need to know to succeed in doing deals and fundraising Dr. Patrik Frei May 2014 Seoul BioKorea Overview Introduction to Valuation Valuation of a companies Valuation of a therapeutic Product Q
More informationIpsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018
Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018 Sales growth of 26.7% 1 for Specialty Care and 2.0% 1,2 for Consumer Healthcare
More informationStifel Presentation November 2018
Stifel Presentation November 2018 Disclaimer This presentation may contain certain forward-looking statements. Such statements reflect current views on, among other things, our markets, activities, projections,
More informationGLOBAL TRANSACTIONS FORECAST
2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential
More informationRadford Review: 2013 Say-on-Pay Results and Trends for the US Life Sciences Sector. One Firm. Complete Solutions.
Radford Review: 2013 Say-on-Pay Results and Trends for the US Life Sciences Sector One Firm. Complete Solutions. 2013 Say-on-Pay Snapshot Overall Russell 3000 Index Results Among Russell 3000 companies
More informationINSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 OncoSec Medical (Nasdaq/ONCS)
More informationMOLOGEN AG: Interim Financial Statements as of March 31, 2010
MOLOGEN AG: Interim Financial Statements as of March 31, 2010 Content Foreword... Page 3 Interim management report for the period from January 1 to March 31, 2010... Page 5 Statement of financial position
More informationTEXAS MULTIFAMILY FOLLOW THE MONEY. THE CAPITAL MARKETS PERSPECTIVE Jeanette I. Rice, Americas Head of Investment Research February 12, 2016
TEXAS MULTIFAMILY FOLLOW THE MONEY THE CAPITAL MARKETS PERSPECTIVE Jeanette I. Rice, Americas Head of Investment Research February 12, 2016 MULTIFAMILY ON TOP OF THE MARKET 2 MONEY IS FOLLOWING MULTIFAMILY
More informationArix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017
Arix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017 CEO s Statement A vote of confidence in the life science sector In February 2017, Arix
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationToday s discussion. Traveler..domestic and international spending, origin, purpose and activities. Lodging data. Regional research
November 29, 2012 Today s discussion. Traveler..domestic and international spending, origin, purpose and activities Lodging data Regional research Massachusett's Travel and Tourism Top Line Numbers Direct
More informationGDP projections for major economies
GDP projections for major economies 214-215 214 215 Australia 2.6% 2.7% Emerging markets 4.9% 5.2% Euro area 1.2% 1.5% Japan 1.4% 1.% United Kingdom 2.9% 2.5% United States 2.8% 3.% Source: IMF WEO. BRIC
More informationTo Our Shareholders 33 44
33 44 33 44 035 Letter from Stefan Oschmann 040 The Executive Board 042 Our Shares Letter from Stefan Oschmann 35 It is a great pleasure for me to write to you for the first time as Chairman of the Executive
More informationNEOVACS SUCCESSFULLY RAISES 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS
PRESS RELEASE PRESS RELEASE PRESS RELEASE NEOVACS SUCCESSFULLY RAISES 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS Paris and Boston, July 31, 2017 7:30 am CET- Neovacs
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,026,977,439.38 Fund Inception Date 03/04/2000 Number of Issuers 96 Bloomberg
More informationADVERUM BIOTECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event
More informationWe believe in in the power of a vision. Investor Presentation
We believe in in the power of a vision. Q1-2008 Investor Presentation Forward-Looking Statements Certain matters discussed in this presentation may be forward-looking statements within the meaning of the
More informationERYTECH TO RAISE 70.5 MILLION IN A PRIVATE PLACEMENT TO U.S. AND EUROPEAN INVESTORS
PRESS RELEASE THIS DOCUMENT MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. THIS PRESS RELEASE IS NOT INTENDED AS AN OFFER AND IS
More informationGalapagos reports record revenues and increased profitability in 2010
Regulated information 4 March 2011 Galapagos reports record revenues and increased profitability in 2010 Revenues 136.6 M (+29%) Net profit 4.4 M ( 09: 3.0 M) Operating profit 1.0 M ( 09: 1.7 M) Year end
More informationFOR IMMEDIATE RELEASE Contact: Ann Marie Gorden/Robert Nihen
cutting through complexity News FOR IMMEDIATE RELEASE Contact: Ann Marie Gorden/Robert Nihen June 24, 2014 KPMG LLP 201-505-6288/201-307-8296 agorden@kpmg.com / rnihen@kpmg.com CINCINNATI, CLEVELAND, ATLANTA
More informationVALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company
VALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company Dr. Patrik Frei September 2015 Brisbane Overview Introduction Valuation of start-up companies Valuation of a therapeutic
More informationPieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MAY 10, 2018 AT 8:00 AM EDT BOSTON,
More informationZipRealty, Inc. Supplemental Data Reclassification of Consolidated Statement of Operations
Reclassification of Consolidated Statement of Operations Effective January 1, 2007, for income statement presentation purposes, we have reclassified sales support and marketing expenses from general and
More informationAssets under management (as previously reported)
Assets under management (as previously reported) For completeness we have included below a five-year analysis of assets under management as previously reported. Going forward, this will be replaced by
More informationNext Edge Bio-Tech Plus Fund
Next Edge Bio-Tech Plus Fund Monthly Commentary as of January 31, 2019 Investing in companies of the future: A unique, well defined process of investing in North American small and mid-capitalization biotechnology
More information** The operating loss for H is after exceptional costs of 41k relating to the termination of the Biomoti acquisition
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six-month period
More informationSTADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41%
Corporate News STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41% STADA interim report after 9 months of 2007: Important items at a glance Strong operative growth continues as expected
More informationKite Pharma Reports First Quarter 2015 Financial Results
May 15, 2015 Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company
More informationOrion Interim Report Q1 Q2/2012
Orion Interim Report Q1 Q2/2012 31 July 2012 Timo Lappalainen President and CEO This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not
More informationCHINA i2i GROUP WECHAT SURVEY
2017 CHINA i2i GROUP WECHAT SURVEY 88% 3 Million $3.4 Billion 690,000 875,000 94% 88% Are Millennials Age 18 39 More than 3 Million Annual International Travelers $3.4 Billion In Annual Shopping Spend
More informationAdequate Procedures: An International Overview
Adequate Procedures: An International Overview Rossana Buzzi, Invensys Jonathan Armstrong, Cordery SCCE 14th Annual Compliance and Ethics Institute 5 October 2014 Legal Disclaimer The views stated herein
More information2015 Dining Trends Survey Results
1 # of participants: 10,727 Gender: Male - 45% / Female - 55% Age: 20s -19% / 30s -17% / 40s -19% / 50s -19% / 60+ - 26% How many times do you typically eat out in restaurants for breakfast, lunch and
More informationWorkshop Presentation: Deal and Product Valuations Nov 2017 NYC, RESI Agenda 1.Overview of product valuation 2.rNPV product valuation 3.Deal structure / Negotiation 4.Case Study 2 Company Mission Independent
More informationFortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 9, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationAgenda. Venture Capital and Valuations
Venture Capital and Valuations Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Venture Capital - Why Valuation?
More informationReturns Based on a $100,000 Investment
A Leading Developer of Stem Cell Treatment Centers Fact Sheet 2016 Bioscience Americas, LLC Fund Data: Series 1: $15,000,000 Minimum Investment: $25,000 Type: Holdings: ) Investor Benefits: Private placement
More informationSustaining Innovation and Access in Europe. Nathalie Moll, Secretary General Brussels, 13 May 2014
Sustaining Innovation and Access in Europe Nathalie Moll, Secretary General Brussels, 13 May 2014 Who we are European Association of Biotechnology Industries Three sectors Red: Healthcare biotechnology
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report Cara Therapeutics (CARA - $14.70) CARA to Benefit from Important Licensing Agreement CARA recently announced that they
More informationInterim results for the six months ended 30 June 2017
Interim results for the six months ended 30 June 2017 Midatech Pharma plc September 2017 Disclaimer THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY
More informationIpsen FY 2017 Results. February 15, 2018
Ipsen FY 2017 Results February 15, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationAbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results
PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent
More informationReal Estate Investment Beyond(?) the Global Credit Crisis
Real Estate Investment Beyond(?) the Global Credit Crisis James Valente (james.valente@ipd.com) Director, North America November 29 th 2011 2011 ipd.com Overview Variation in regional trends Global investment
More information2012 SUMMARY REPORT PG 1
2012 SUMMARY REPORT PG 1 100 MILLION PEOPLE City of Hope scientists helped create medicines that benefit 100 million people worldwide each year. 15 FIRST-IN-HUMAN CLINICAL TRIALS City of Hope has created
More informationPharming Group reports financial results for the first nine months of 2017
Pharming Group reports financial results for the first nine months of 2017 Strong increase in revenues boosts operating profitability and positive cash flow Strong outlook with increasing revenues expected
More informationHow A No-Deal Brexit Would Affect Life Sciences Cos.
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com How A No-Deal Brexit Would Affect Life Sciences
More information1 sur 9 26/07/ :19
1 sur 9 26/07/2012 13:19 Print Page Close Window Press Releases Celgene Reports Second Quarter 2012 Operating and Financial Results Total Revenue of $1.37 Billion and Net Product Sales of $1.34 Billion,
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationevestment Alliance, LLC - All Rights Reserved
HEDGE FUND REGIONAL COMPOSITIONS Summary The following pages rank the regional distribution of active hedge fund firms and their active products (funds), based on information contained in evestment s research
More informationASTRAZENECA REFINES ITS FINANCIAL REPORTING IN LINE WITH EVOLVING BUSINESS MODEL
6 March 2015 ASTRAZENECA REFINES ITS FINANCIAL REPORTING IN LINE WITH EVOLVING BUSINESS MODEL trazeneca today announces an update to the presentation of its Statement of Comprehensive Income, which will
More informationPage 1 of 6 Contact Us Legal Sitemap Search About Us Soliris & PNH R & D Investors Careers News Archives Highlights Media Kit Inquiries Alexion Reports Second Quarter 2011 Results -- Soliris (eculizumab)
More informationSyneos Health, Inc. Investment Research Presentation
Syneos Health, Inc. Investment Research Presentation NasdaqGS: SYNH Month Sector: Day, Healthcare 20XX Senior Analyst: Jose Grullon Junior Analysts: Garbis Chekerdjian, Ignacio Fimbres Spring 2018 1 Valuation
More information1. The Board of Directors' report on the Company's activities in the past year.
AGENDA 1. The Board of Directors' report on the Company's activities in the past year. 2. Presentation of the Annual Report for adoption. 3. A proposal from the Board of Directors regarding the application
More informationNeuroVive resolves on a Rights issue of MSEK for continued drug development, and new publication date of the 2018 Year End Report
NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report Lund, Sweden, 10 December 2018, NeuroVive Pharmaceutical AB (publ)
More informationThe Economic Backdrop When will this cycle end?
The Economic Backdrop When will this cycle end? How far are we into the current economic expansion? Current expansion in 8 th year; 4 th longest since 1960 Length of economic expansions (months) Apr-91-Feb-01
More informationCapital Link CEF and Global ETF Forum April 27, 2017
Capital Link CEF and Global ETF Forum April 27, 2017 THW THQ HQH HQL Forward Looking Statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other
More informationHeidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018 Exclusive research agreement signed with Magenta for the development of Antibody Targeted Amanitin Conjugates License
More informationAVEO Reports First Quarter 2018 Financial Results and Provides Business Update
AVEO Reports First Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. May 8, 2018 AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March
More informationSECTION 03: Quantitative analysis
Researc Researc Researc 8m 9% 7m 7,689,644.9 8% 7% 6m 588,574,879.6 6% 5% 4% 3% 2% Amount 5m 4m 3m 258,489,815.2 381,51,62.7 494,118,741. 212 213 1% % 2m 1m 7,77,161.45 139,871,673.7 26-7 27-8 28-9 29-1
More informationCompetitive Alternatives. Special Report: Focus on Tax Edition. competitivealternatives.com. Corporate Sponsors
Competitive Alternatives Special Report: Focus on Tax 2012 Edition competitivealternatives.com Corporate Sponsors ii Competitive Alternatives 2012 Contents 1. Summary 1 2. Measuring Total Tax Costs 6 3.
More information2018 Edelman Trust Barometer
2018 Edelman Trust Barometer Snapshot Australia #TrustBarometer Trust Index A World of Distrust Average trust in institutions, general population, 2017 vs. 2018 Global Trust Index remains at distruster
More informationThe Global Tax Reset 2017 Audit Committee Symposium
The Global Tax Reset Copyright 2017 Deloitte Development LLC. All rights reserved. 2017 Audit Committee Symposium Anticipate. Navigate. Focus. 1 The Global Tax Reset General context Multinational companies
More informationBuilding global leaders in healthcare...
Building global leaders in healthcare... Annual report and accounts 2017 ... to deliver transformational treatments for patients Syncona Syncona is a leading FTSE 250 company focused on investing in and
More informationUCB half year results 2012: On track for growth
UCB half year results 2012: On track for growth In the first half 2012, total revenue increased by 2% 1 to EUR 1 706 million. Cimzia, Vimpat and Neupro reaching combined net sales of EUR 413 million (+45%
More informationNilfisk Q2 Interim Report 2018 Webcast presentation August 14
Webcast presentation August 14 Agenda 1 2 3 4 5 Highlights Business unit update Financials Outlook 2018 Q&A 2 Strong financial performance in Q2 Financial highlights Strong financial performance with organic
More informationSmall-Cap Research. Oncolytics Biotech Inc. April 12, 2017 John D. Vandermosten, CFA (ONCYF - OTCQX) REOLYSIN Clinical Development Plan SUMMARY DATA
Small-Cap Research April 12, 2017 John D. Vandermosten, CFA 312-265-9588 / jvandermosten@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Oncolytics Biotech Inc. REOLYSIN Clinical
More informationAfrica Pharmaceutical
Africa Pharmaceutical (title Sector: ) Opportunities and Challenges Dr Feng Zhao Manager, Health Division Human Development Department, African Development Bank 1 The New Africa Economy Africa Rising:
More informationMultifamily Outlook. United States Fall 2014
Multifamily Outlook United States Fall 2014 Markets continue to perform at peak levels... with nearterm, pocketed softening on the horizon On the heels of seven quarters of peak-level investment sale volumes,
More informationSession 11. Fiscal Policy
Session 11. Fiscal Policy Government size Budget balances Fiscal Policy over the business cycle Debt and sustainability Understanding Fiscal Policy: Government size Government size varies across countries.
More informationU.S. Investment Outlook
U.S. Investment Outlook Quarterly Investor Research update Q2 2015 U.S. Investment overview 37% 21% 15% 15% U.S. cities dominating global investment activity Top 20 Cities for Transactional Volumes H1
More informationCYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported)
More informationAbout this survey. less optimistic than other major economies. Marcoeconomic pressure in the Eurozone,
Outlook April October 2013 About this survey is a regular survey of senior executives from large companies around the world, conducted by the Economist Intelligence Ernst & Young clients and contacts and
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Stamford Ft. Lauderdale EQUITY RESEARCH Company Report Cytori Therapeutics (CYTX - $ 2.07) Management Updates on Lorem Vascular Partnership and Others This
More informationUS Hotel Industry Overview. Chris Crenshaw
US Hotel Industry Overview Chris Crenshaw ccrenshaw@str.com July 2014 (12 MMA): All Signs Point To A Sellers Market % Change Room Supply* 1.8 bn 0.8% Room Demand* 1.1 bn 3.4% Occupancy 63 % 2.6% A.D.R.*
More informationClavis Pharma ASA. First Quarter Report 2008
Clavis Pharma ASA First Quarter Report 2008 Clavis Pharma uses its proprietary Lipid Vector Technology (LVT) to develop new and superior pharmaceuticals by improving already established drugs. The Company
More information